Good morning, myeloma world.

We've got a lot of new myeloma-related research to cover today, so we'll get right down to business.

The first two studies we will review are related to autologous (own) stem cell transplantation.

One study looks at whether myeloma cells make their way into the infusion of a patient's own stem cells that a patient gets during the autologous transplant process. The study finds that, in some cases, myeloma cells do make it into the stem …

Good morning, myeloma world.

It's been a very chilly morning here at Myeloma Morning Headquarters. After teasing us with summerlike temperatures the past few weeks, Mother Nature has decided she's not done with the part of the thermometer below freezing.

We'll be focusing on two new research studies in today's report.

The first study looks at outcomes of allogeneic (donor) stem cell trans­plan­ta­tion for multiple myeloma. Using outcomes from a single U.S. treatment center, the study authors find that whether …

Good morning, myeloma world.

It's just Tuesday, and already the week is getting in­ter­est­ing. We'll be reporting on just two myeloma-related news items today, but one of them is the kind of news we don't see here at Myeloma Morning very often.

In particular, the German bio­tech com­pany MorphoSys has sued Janssen Biotech and Genmab, the two com­pa­nies that have devel­oped and mar­keted Darzalex (dara­tu­mu­mab). MorphoSys contends that sales of Darzalex infringe on a MorphoSys …

Good morning, myeloma world.

It truly was a dark and stormy night when we sat down early yesterday to start writing the next edition of Myeloma Morning. A spring windstorm was howling about outside and, before we knew it, the wily gusts had conspired to knock out electricity at Myeloma Morning Headquarters.

Fortunately, the watts and volts are back in working order, and we're glad to be writing for you again.

All the news we cover in today's

Good morning, myeloma world.

After a busy week here at Myeloma Morning Headquarters, we're pleased to report that things are a bit more relaxed today. We're not sure if it's the weekend, or the cooler, overcast weather outside. Whatever the reason, we're enjoying the somewhat slower pace.

That pace is reflected in what we'll be covering in today's edition of Myeloma Morning. We'll be discussing just three new myeloma research articles.

The first article is a discussion of how to …

A belated good morning to you, myeloma world.

How has your Friday been so far? Has April Fools' Day brought joy, con­ster­na­tion, or a bit of both to your life?

We were caught off guard this morning by some news that came out just as we were about to wrap up this edition of Myeloma Morning. But the news, which con­cerns Darzalex, is good, so we definitely won't be com­plaining.

Here are today's myeloma-related headlines.

First, Darzalex (daratumuab) is …

Good morning, myeloma world.

We all should have seen this coming.

After days and days of having no major myeloma business news to cover here at Myeloma Morning, what hap­pens? Suddenly, there's not just one new myeloma-related business devel­op­ment to discuss. And not just two. But a full three such news items to review.

So let's start with those devel­op­ments, after which we'll take a quick look at a new research article and what's been going on …